Bangladesh: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
The project will provide the Government of Bangladesh with timely financing for procuring safe and effective vaccines against the coronavirus disease (COVID-19) based on an agreed list of eligible expenditures. It will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX). Ongoing technical assistance (TA) will help strengthen the vaccine delivery system. The project is aligned with three operational priorities of the Asian Development Bank (ADB) Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. It is also aligned with ADB's country partnership strategy for Bangladesh, 2016-2020 in the priority areas of improving human capital and health care, and promoting gender equality
Project Details
-
Project Officer
Hoque, Uzma S.
South Asia Department
Request for information -
Country
Bangladesh -
Sector
- Health
| Project Name | Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility | ||||||||
| Project Number | 55077-001 | ||||||||
| Country | Bangladesh |
||||||||
| Project Status | Active | ||||||||
| Project Type / Modality of Assistance | Loan |
||||||||
| Source of Funding / Amount |
|
||||||||
| Strategic Agendas | Inclusive economic growth Regional integration |
||||||||
| Drivers of Change | Gender Equity and Mainstreaming Knowledge solutions Partnerships |
||||||||
| Sector / Subsector | Health / Disease control of communicable disease |
||||||||
| Gender Equity and Mainstreaming | Effective gender mainstreaming | ||||||||
| Description | The project will provide the Government of Bangladesh with timely financing for procuring safe and effective vaccines against the coronavirus disease (COVID-19) based on an agreed list of eligible expenditures. It will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX). Ongoing technical assistance (TA) will help strengthen the vaccine delivery system. The project is aligned with three operational priorities of the Asian Development Bank (ADB) Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. It is also aligned with ADB's country partnership strategy for Bangladesh, 2016-2020 in the priority areas of improving human capital and health care, and promoting gender equality | ||||||||
| Project Rationale and Linkage to Country/Regional Strategy | Since the first case of COVID-19 was confirmed in Bangladesh in March 2020, 776,257 cases have been confirmed and 12,005 people have died from the virus as of 11 May 2021. The pandemic has resulted in high costs to the country's overall health, well-being, and the economy. Bangladesh is currently experiencing a second wave, which has led to a rapid spike in new cases, with the highest number of deaths (112) in a single day on 19 April 2021. The resurgence in infections threatens to incur prolonged health and economic costs. Recognizing the need for vaccinations, the government acted swiftly to roll out vaccinations starting 7 February 2021. The government has secured a pipeline of 33.2 million doses and more than 9.3 million people have been vaccinated as of 9 May 2021. The government aims to inoculate 80% of its population. However, Bangladesh's vaccine needs have not been fully met and a significant share of the targeted population is yet to be vaccinated. It requires timely financing support to procure safe and effective vaccines, and avert prolonged risks from the pandemic. | ||||||||
| Impact | Accelerated health, social, and economic recovery of the COVID-19 affected population in Bangladesh | ||||||||
| Project Outcome | |
|---|---|
| Description of Outcome | Target populations vaccinated against COVID-19 |
| Progress Toward Outcome | |
| Implementation Progress | |
| Description of Project Outputs | Safe and effective COVID-19 vaccines delivered |
| Status of Implementation Progress (Outputs, Activities, and Issues) | |
| Geographical Location | Nation-wide |
| Safeguard Categories | |
|---|---|
| Environment | C |
| Involuntary Resettlement | C |
| Indigenous Peoples | C |
| Summary of Environmental and Social Aspects | |
|---|---|
| Environmental Aspects | The project will support the procurement of vaccines and will not entail civil works or other activities with potential for significant adverse impacts on the environment. |
| Involuntary Resettlement | The project will not require any land acquisition or lead to any involuntary resettlement impacts or involuntary land use restriction. |
| Indigenous Peoples | The tribes, minor races, ethnic sects, and ethnic communities will not be targeted as a distinct and vulnerable IP group but may benefit as individual IPs. |
| Stakeholder Communication, Participation, and Consultation | |
| During Project Design | |
| During Project Implementation | The participation plan will not be prepared because while the participation of CSOs has been envisaged, CSOs are not the major interest holder in this program. |
| Business Opportunities | |
|---|---|
| Procurement | Procurement will be undertaken in a manner consistent with simplified and expedient procedures permitted under the ADB Procurement Policy (2017, as amended from time to time) and Procurement Regulations for ADB Borrowers (2017, as amended from time to time). Since the project will be financed under APVAX, ADB member country eligibility restrictions will be waived and universal procurement will apply. The procurement of a proportion of the vaccines may be done through COVAX. In addition, given the severely constrained vaccine market, the MOHFW may negotiate directly with vaccine manufacturers to agree on bilateral contracts, and direct contracting with UNICEF. Before being confirmed as an eligible expenditure under the loan, ADB will review all bilateral vaccine agreements. Value for money in procurement will be achieved by (i) selecting vaccines that are best suited to the domestic supply chain; (ii) identifying vaccines that will efficiently meet the project disbursement conditions; (iii) engaging with manufacturers that have advantageous vaccine delivery timelines; and (iv) entering into agreements on terms and conditions that are reasonable, noting the currently constrained market for vaccines globally. ADB's Anticorruption Policy (1998, as amended to date) will apply to all contracts to be financed under the loan. |
| Responsible ADB Officer | Hoque, Uzma S. |
| Responsible ADB Department | South Asia Department |
| Responsible ADB Division | Human and Social Development Division, SARD |
| Executing Agencies |
Finance Division, MOF (EA) Mr.Molla Mansur Ahmed [email protected] Bangladesh Secretariat, Dhaka-1000 Bangladesh |
| Timetable | |
|---|---|
| Concept Clearance | 30 Dec 2022 |
| Fact Finding | 29 Mar 2021 to 05 Apr 2021 |
| MRM | 10 May 2021 |
| Approval | 22 Jun 2021 |
| Last Review Mission | - |
| Last PDS Update | 22 Jun 2021 |
Loan 4078-BAN
| Milestones | |||||
|---|---|---|---|---|---|
| Approval | Signing Date | Effectivity Date | Closing | ||
| Original | Revised | Actual | |||
| 22 Jun 2021 | 24 Jun 2021 | 05 Jul 2021 | 30 Nov 2024 | - | - |
| Financing Plan | Loan Utilization | ||||
|---|---|---|---|---|---|
| Total (Amount in US$ million) | Date | ADB | Others | Net Percentage | |
| Project Cost | 470.00 | Cumulative Contract Awards | |||
| ADB | 470.00 | 18 Oct 2021 | 447.27 | 0.00 | 95% |
| Counterpart | 0.00 | Cumulative Disbursements | |||
| Cofinancing | 0.00 | 18 Oct 2021 | 441.30 | 0.00 | 94% |
Loan 4079-BAN
| Milestones | |||||
|---|---|---|---|---|---|
| Approval | Signing Date | Effectivity Date | Closing | ||
| Original | Revised | Actual | |||
| 22 Jun 2021 | 24 Jun 2021 | 05 Jul 2021 | 30 Nov 2024 | - | - |
| Financing Plan | Loan Utilization | ||||
|---|---|---|---|---|---|
| Total (Amount in US$ million) | Date | ADB | Others | Net Percentage | |
| Project Cost | 470.00 | Cumulative Contract Awards | |||
| ADB | 470.00 | 18 Oct 2021 | 300.00 | 0.00 | 64% |
| Counterpart | 0.00 | Cumulative Disbursements | |||
| Cofinancing | 0.00 | 18 Oct 2021 | 450.00 | 0.00 | 96% |
Project Data Sheets (PDS) contain summary information on the project or program. Because the PDS is a work in progress, some information may not be included in its initial version but will be added as it becomes available. Information about proposed projects is tentative and indicative.
The Access to Information Policy (AIP) recognizes that transparency and accountability are essential to development effectiveness. It establishes the disclosure requirements for documents and information ADB produces or requires to be produced.
The Accountability Mechanism provides a forum where people adversely affected by ADB-assisted projects can voice and seek solutions to their problems and report alleged noncompliance of ADB's operational policies and procedures.
In preparing any country program or strategy, financing any project, or by making any designation of, or reference to, a particular territory or geographic area in this document, the Asian Development Bank does not intend to make any judgments as to the legal or other status of any territory or area.
Safeguard Documents See also: Safeguards
Safeguard documents provided at the time of project/facility approval may also be found in the list of linked documents provided with the Report and Recommendation of the President.
None currently available.
Evaluation Documents See also: Independent Evaluation
None currently available.
Related Publications
None currently available.
The Access to Information Policy (AIP) establishes the disclosure requirements for documents and information ADB produces or requires to be produced in its operations to facilitate stakeholder participation in ADB's decision-making. For more information, refer to the Safeguard Policy Statement, Operations Manual F1, and Operations Manual L3.
Requests for information may also be directed to the InfoUnit.
-
ADB Approves $940 Million for Bangladesh COVID-19 Vaccines
The Asian Development Bank has approved a loan package of $940 million for the Government of Bangladesh to purchase safe and effective vaccines against the coronavirus disease (COVID-19).
Tenders
No tenders for this project were found.
Contracts Awarded
No contracts awarded for this project were found
Procurement Plan
| Title | Document Type | Document Date |
|---|---|---|
| Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility: Procurement Plan | Procurement Plans | Mar 2021 |